CATHOLIC KWANDONG UNIVERSITY INDUSTRY FOUNDATION;SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION;서울대학교산학협력단;한국식품연구원;가톨릭관동대학교산학협력단;KOREA FOOD RESEARCH INSTITUTE
发明人:
KIM, HYO JIN,김효진,CHIN, YOUNG WOOK,진영욱,KANG, WOO KYUNG,강우경,LEE, KYUN HEE,이건희,MOON, SUNG JIN,문성진,KIM, HYO JINKR,CHIN, YOUNG WOOKKR,KANG, WOO KYUNGKR,LEE, KYUN HEEKR,MOON, SUNG JINKR
申请号：
KR1020180054652
公开号：
KR1020180125895A
申请日:
2018.05.14
申请国别(地区):
KR
年份:
2018
代理人:
摘要：
The present invention relates to a pharmaceutical composition for preventing or treating a disease caused by accumulation of a uremic toxin and a food composition for improving a disease caused by the accumulation of the uremic toxin using a lactobacillus sp. KCCM 11826P strain. According to the present invention, the Lactobacillus sp. KCCM 11826P strain sorted can reduce concentration of an indoxyl sulfate in blood. In other words, according to the present invention, the Lactobacillus sp. KCCM 11826P can effectively control the uremic toxin in the blood by removing the uremic toxin in a small intestine when taking the Lactobacillus sp. KCCM 11826P. Also, according to the present invention, the Lactobacillus sp. KCCM 11826P can be provided at very low prices in comparison with Kemezin which is an existing uremic toxin adsorption and reduction agent and can be developed as yogurt, powder, or nourishing food for a patient using a property of the strain. Therefore, the Lactobacillus sp. KCCM 11826P is very easily taken in comparison with the existing uremic toxin reduction agent. Also, according to the present invention, the Lactobacillus sp. KCCM 11826P which is Lactobacillus can stay in the intestine for a relatively long time and, therefore, has long intake intervals in comparison to the existing adsorption agent. Also, the Lactobacillus sp. KCCM 11826P can effectively control the uremic toxin in the blood even with a few intakes.본 발명은 락토바실러스 sp. (Lactobacillus sp.) KCCM 11826P 균주를 이용한, 요독물질 축적으로 말미암아 발생하는 질환의 개선용 식품 조성물, 요독물질 축적으로 말미암아 발생하는 질환의 예방 또는 치료용 약학 조성물에 관한 것으로, 본 발명에서 선별한 락토바실러스 sp. (Lactobacillus sp.) KCCM 11826P는 혈중 내 요독물질(indoxyl sulfate)의 농도를 줄일 수 있다. 즉, 본 발명의 락토바실러스 sp. (Lactobacillus sp.) KCCM 11826P를 섭취할 경우, 소장 내 요독물질의 제거 등을 통하여 혈중 요독물질을 효과적으로 조절할 수 있는 것이다.또한, 본 발명에서 선별한 락토바실러스 sp. KCCM 11826P는 기존의 요독물질 흡착 저감제인 Kremezin에 비하여 매우 저렴한 가격으로 복용이 가능하고, 균주의 특성상 요구르트, 분말 또는 환자의 영양식 등으로 개발이 가능하므로, 기존의 요독물질 저감제보다 복용이 매우 편리한 장점이 있다.또한, 본 발명의 유산균인 락토바실러스 sp
